TMPRSS2 and COVID-19: The expression of TMPRSS2, the co-factor of ACE2, was also significantly higher in lung cancer patients than in the general population (Wilcoxon’s rank-sum test, P < 0.001) (Figure 1H), suggesting that patients with lung cancer were more likely to be susceptible to COVID-19.